Moroctocog alfa (BDDrFVIII)

Specification

• Cat#: THP-0085
• Product Name: Moroctocog alfa (BDDrFVIII)
• Description: The product, also known as B domain deleted recombinant factor VIII, is a recombinant DNA-based product with functional characteristics comparable to those of endogenous coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. The product is identical in sequence to endogenously produced Factor VIII, but does not contain the B-domain, which has no known biological function. The product is produced through recombinant DNA technology and purification, resulting in a 1438 amino acid, 170 kDa protein. Clinical evaluation has shown that BDDrFVIII is pharmacokinetically equivalent to full-length recombinant FVIII.
• Sequences: Not Available
• Species: Human
• Molecular Weight: 173000.0 Da (glycosylated)
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 284036-24-4
• Formula: Not Available
• Endotoxin Level: <0.001 EU per 1 μg by the LAL method
• Biological Activity: 250U-3000U/vial

Pharmaceutical Information

• Pharmaceutical Application: Moroctocog alfa
• Applications: The product is approved by Health Canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia). The product is also approved by the European Medicines Agency for the treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital factor VIII deficiency).
• Examples of Clinical Use: Bleeding in Haemophilia A (congenital factor VIII deficiency).
• Pharmacodynamics: Antihemophilic Factor binds factor IXa along with calcium and phospholipid, which converts factor X to factor Xa to facilitate the clotting cascade.
• Mechanism of action: Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia). As factor VIII is the specific clotting factor deficient in patients with hemophilia A, replacement of clotting factor with Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is the cornerstone of the prevention and treatment of bleeding for this disorder.
• Affected organisms: Not Available
• Targets: Target 1. Coagulation factor X; Target 2. Phytanoyl-CoA dioxygenase, peroxisomal; Target 3. Coagulation factor IX; Target 4. Asialoglycoprotein receptor 2; Target 5. 78 kDa glucose-regulated protein; Target 6. Calreticulin; Target 7. Calnexin; Target 8. Protein ERGIC-53; Target 9. Prolow-density lipoprotein receptor-related protein 1; Target 10. Multiple coagulation factor deficiency protein 2; Target 11. von Willebrand factor; Enzyme 1. Prothrombin; Enzyme 2. Vitamin K-dependent protein C